Skip to main content
TNXP
NASDAQ Life Sciences

Tonix Pharmaceuticals 提升至 Nasdaq 全球精选市场

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$13.86
Mkt Cap
$178.777M
52W Low
$6.76
52W High
$69.97
Market data snapshot near publication time

summarizeSummary

Tonix Pharmaceuticals 宣布其普通股已获批从 Nasdaq 资本市场转移到 Nasdaq 全球精选市场，今日开始交易。这次提升表明该公司符合 Nasdaq 最高的金融和公司治理标准，这是对市场的一个积极信号。预计这一举动将提高公司在机构投资者中的知名度，提高流动性，并扩大市场认可度。投资者将密切关注这一提高市场地位是否会转化为机构持股率和交易量的增加，从而可能影响未来的资本筹集或合作伙伴关系。

在该公告发布时，TNXP的交易价格为$13.86，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.8亿。 52周交易区间为$6.76至$69.97。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed TNXP - Latest Insights

TNXP
Apr 29, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Tonix Pharma Advances Lyme Disease Candidate TNX-4800 to Planned Phase 2, Reports Positive Phase 1 Data
Sentiment: Positive
View Wiseek Article
TNXP
Apr 23, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
7
Tonix Pharmaceuticals Reports Encouraging Preclinical Immuno-Oncology Data at AACR Meeting
Sentiment: Positive
View Wiseek Article
TNXP
Mar 31, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Tonix Pharmaceuticals Announces Positive Phase 1 Data for Lyme Disease Candidate TNX-4800, Outlines Phase 2 Study
Sentiment: Positive
View Wiseek Article
TNXP
Mar 30, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on Critical Reverse Stock Split and Dilutive Incentive Plan Amidst Delisting Concerns
Sentiment: Negative
View Wiseek Article
TNXP
Mar 26, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Tonix Pharma Doses First Patient in Phase 1 Migraine Study for TNX-1900
Sentiment: Positive
View Wiseek Article
TNXP
Mar 20, 2026, 5:12 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Shareholders to Vote on Reverse Stock Split and Evergreen Dilutive Stock Plan Amidst Going Concern Warning
Sentiment: Negative
View Wiseek Article
TNXP
Mar 18, 2026, 5:03 PM EDT
Filing Type: 4
Importance Score:
7
CEO Seth Lederman Buys $223K in Shares Following Going Concern Warning
Sentiment: Positive
View Wiseek Article
TNXP
Mar 12, 2026, 5:30 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Tonix Pharmaceuticals' Q4 Loss Hits $3.98 Per Share
Sentiment: Negative
View Wiseek Article
TNXP
Mar 12, 2026, 5:29 PM EDT
Filing Type: 10-K
Importance Score:
9
Auditor Raises Substantial Doubt on Tonix Pharma's Going Concern Amidst Deep Losses and Short Cash Runway
Sentiment: Negative
View Wiseek Article
TNXP
Mar 10, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Tonix Pharmaceuticals Presents Strong Post-Hoc Phase 3 Data for FDA-Approved Fibromyalgia Drug TONMYA™
Sentiment: Positive
View Wiseek Article